Cargando…
Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide with a minority of patients being diagnosed early enough for curative-intent interventions. We report the first use of preoperative cabozantinib plus nivolumab to successfully downstage what presented as unresectabl...
Autores principales: | Ho, Won Jin, Sharma, Gaurav, Zhu, Qingfeng, Stein-O'Brien, Genevieve, Durham, Jennifer, Anders, Robert, Popovic, Aleksandra, Mo, Guanglan, Kamel, Ihab, Weiss, Matthew, Jaffee, Elizabeth, Fertig, Elana J, Yarchoan, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682468/ https://www.ncbi.nlm.nih.gov/pubmed/33219090 http://dx.doi.org/10.1136/jitc-2020-000932 |
Ejemplares similares
-
Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity
por: Ho, Won Jin, et al.
Publicado: (2021) -
Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
por: Zhang, Shuming, et al.
Publicado: (2023) -
Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
por: Zhang, Shuming, et al.
Publicado: (2023) -
Informing virtual clinical trials of hepatocellular carcinoma with spatial multi-omics analysis of a human neoadjuvant immunotherapy clinical trial
por: Zhang, Shuming, et al.
Publicado: (2023) -
Transcriptomic forecasting with neural ordinary differential equations
por: Erbe, Rossin, et al.
Publicado: (2023)